|
Amanda Silva PharmD, PhD
Research director
Université Paris Cité
France
|
Amanda K. A. Silva – marital name Brun (Pharmacist, CNRS researcher, 39 years old, female) obtained a PhD on Pharmaceutical Technology in 2008 and a second PhD in Cellular and Molecular Biology in 2010. In 2013, Amanda obtained a tenured CNRS researcher position in France. In 2021, Amanda obtained a CNRS research director position. She works at Laboratoire Matière et Systèmes Complexes (MSC, UMR 7057) at Université Paris Cité, mainly focusing on high-performance approaches for (i) EV production based on a turbulent flow stimulation directly in bioreactors; (ii) EV loading for anti-tumor therapy as well as (iii) EV administration in a hydrogel for regenerative medicine (fistula therapy and esophageal stricture prevention). This research set the basis and the patent portfolio (4 licensed patent applications) for founding 2 spin-offs: EverZom (a bio-production start-up – 19 employees) and Evora Bioscience (a biotherapy start-up – 5 employees). Amanda actively contributes to them as chief scientific officer (CSO). Amanda was awarded the CNRS Innovation Medal in 2021 and “Prix des innovateurs en santé'' from Région Île-de-France in 2020. Amanda has recently launched and co-coordinated the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France'' together with a clinician colleague to address regulatory issues on EV-based biotherapies. Amanda co-coordinates the associative project DIM Bioconvergence pour la Santé (BioconvS, 12.5 M€) structuring and accelerating innovation on bioproduction, biotherapies and synthetic biology at Region Ile de France. Amanda published 70 papers. Her current research projects on EV bioengineering are funded by an ERC grant (1.5 M€) and by the Grand défi Biomédicament grant (1.4 M€) she coordinates.